Corvus Pharmaceuticals, Inc.
HealthcareNASDAQ:CRVS · NASDAQ Global Market
+$0.33 today
Vol 1.02M · Avg 1.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-25.0%
avg -46.6%
ROIC
-69.1%
avg -52.8%
ROA
-21.5%
avg -44.6%
Analysis
ROA is currently the strongest return metric at -21.5% versus its period average of -44.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Leiv Lea | Chief Financial Officer | $411,948.00 | — | 72 | $400,000.00 | 0.48% |
William Benton Jones | Senior Vice President of Pharmaceutical Development | $366,115.00 | — | 60 | $400,000.00 | 0.48% |
Peter A. Thompson FACP | Co-Founder & Independent Director | $47,000.00 | — | 66 | $165,000.00 | 0.20% |
Richard A. Miller | Co-Founder, President, Chief Executive Officer & Chairman of the Board | $42,566.00 | — | 75 | $1.19M | 1.42% |
Jeffrey S. Arcara | Senior Vice President & Chief Business Officer | — | — | 57 | $100,000.00 | 0.12% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$83,453.32
Sells
2
$9.78M
Net Sentiment
$9.70M
Net selling
Most Active
MILLER RICHARD A MD
2 transactions
Analysis
Insiders reported 2 buys worth $83,453.32 and 2 sells worth $9.78M over the last 12 months. That adds up to net selling of $9.70M. MILLER RICHARD A MD was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Absci Corporation
NASDAQ:ABSI
$1.06B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages CRVS?
Corvus Pharmaceuticals, Inc. (CRVS) lists 5 active executives. The top listed executive is Richard A. Miller, Co-Founder, President, Chief Executive Officer & Chairman of the Board.
Are CRVS insiders buying or selling?
Recent insider activity shows net selling of $612,455.34.
Explore More
Continue the stock analysis
Jump to another research area for this company.